Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - vericiguat, quantity: 2.5 mg - tablet, film coated - excipient ingredients: magnesium stearate; croscarmellose sodium; lactose monohydrate; titanium dioxide; microcrystalline cellulose; purified talc; hypromellose; sodium lauryl sulfate - verquvo? is indicated in addition to standard of care therapy for the treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction less than 45[percent] who are stabilised after a recent heart failure decompensation event requiring admission and/or iv diuretic therapy (see section 5.1 pharmacodynamic properties ? clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - vericiguat, quantity: 10 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; hypromellose; purified talc; titanium dioxide; croscarmellose sodium; sodium lauryl sulfate; iron oxide yellow; magnesium stearate - verquvo? is indicated in addition to standard of care therapy for the treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction less than 45[percent] who are stabilised after a recent heart failure decompensation event requiring admission and/or iv diuretic therapy (see section 5.1 pharmacodynamic properties ? clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - valsartan, quantity: 51.4 mg; sacubitril, quantity: 48.6 mg - tablet, film coated - excipient ingredients: purified talc; colloidal anhydrous silica; crospovidone; titanium dioxide; hypromellose; hyprolose; macrogol 4000; magnesium stearate; iron oxide red; microcrystalline cellulose; iron oxide yellow - entresto is indicated in adult patients for the treatment of chronic heart failure (nyha class ii-iv) with reduced ejection fraction.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - valsartan, quantity: 25.7 mg; sacubitril, quantity: 24.3 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; crospovidone; iron oxide red; titanium dioxide; macrogol 4000; hypromellose; hyprolose; magnesium stearate; microcrystalline cellulose; iron oxide black; purified talc - entresto is indicated in adult patients for the treatment of chronic heart failure (nyha class ii-iv) with reduced ejection fraction.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - valsartan, quantity: 102.8 mg; sacubitril, quantity: 97.2 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; iron oxide black; magnesium stearate; titanium dioxide; iron oxide red; purified talc; crospovidone; hypromellose; macrogol 4000; hyprolose; microcrystalline cellulose - entresto is indicated in adult patients for the treatment of chronic heart failure (nyha class ii-iv) with reduced ejection fraction.

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - sitagliptin phosphate monohydrate, quantity: 32.13 mg (equivalent: sitagliptin, qty 25 mg) - tablet, film coated - excipient ingredients: calcium hydrogen phosphate; magnesium stearate; croscarmellose sodium; microcrystalline cellulose; sodium stearylfumarate; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - xelevia (sitagliptin phosphate monohydrate) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus as: - monotherapy when metformin is considered inappropriate due to intolerance; or - in combination with other anti-hyperglycaemic agents, including insulin,(see 5.1 pharmacodynamic properties, clinical trials, 4.5 interactions with other medicines and other forms of interactions for available data on different add-on combination therapies.

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - sitagliptin phosphate monohydrate, quantity: 64.25 mg (equivalent: sitagliptin, qty 50 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; calcium hydrogen phosphate; croscarmellose sodium; sodium stearylfumarate; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - xelevia (sitagliptin phosphate monohydrate) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus as: - monotherapy when metformin is considered inappropriate due to intolerance; or - in combination with other anti-hyperglycaemic agents, including insulin,(see 5.1 pharmacodynamic properties, clinical trials, 4.5 interactions with other medicines and other forms of interactions for available data on different add-on combination therapies.

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - sitagliptin phosphate monohydrate, quantity: 128.5 mg (equivalent: sitagliptin, qty 100 mg) - tablet, film coated - excipient ingredients: calcium hydrogen phosphate; magnesium stearate; croscarmellose sodium; microcrystalline cellulose; sodium stearylfumarate; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - xelevia (sitagliptin phosphate monohydrate) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus as: - monotherapy when metformin is considered inappropriate due to intolerance; or - in combination with other anti-hyperglycaemic agents, including insulin,(see 5.1 pharmacodynamic properties, clinical trials, 4.5 interactions with other medicines and other forms of interactions for available data on different add-on combination therapies.

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - levonorgestrel, quantity: 100 microgram; ethinylestradiol, quantity: 20 microgram - tablet, film coated - excipient ingredients: gelatin; macrogol 4000; magnesium stearate; maize starch; lactose monohydrate; titanium dioxide; hypromellose - oral contraception

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - levonorgestrel, quantity: 150 microgram; ethinylestradiol, quantity: 30 microgram - tablet, film coated - excipient ingredients: gelatin; hypromellose; iron oxide yellow; titanium dioxide; magnesium stearate; lactose monohydrate; maize starch; macrogol 4000 - oral contraception